ImmVira Starts China/US Phase II Trial of Oncolytic Virus Therapy for Cancer
June 14, 2021 at 04:29 AM EDT
ImmVira of Shenzhen has dosed the first patients in a China/US Phase II trial of its lead drug, an oncolytic virus product. MVR-T3011 is a proprietary next-gen, genetically modified oncolytic herpes simplex virus (oHSV) delivered to the tumor. It was developed on a novel virus backbone design that was driven by ImmVira's insights into oncolytic viruses and recombinant gene expertise. In its Phase I trials, MVR-T3011 showed promising safety and efficacy. It will be tested in solid tumors and melanoma. More details.... Share this with colleagues: // //